Home
About +
Our Story
Meet the Team
FAQs
Our Science +
Inhaled IFN-β
Clinical Trials
Publications
Investors +
Reports & Presentations
Investor News Archive
Major Shareholders & Advisers
Shareholder Information
Corporate Governance
News +
Press Releases
Factsheets
TR-1/Options Press Release Archive
Careers
Contact
Home
About
Our Science
Investors
News
Careers
Contact
Back
Our Story
Meet the Team
FAQs
Back
Inhaled IFN-β
Clinical Trials
Publications
Back
Reports & Presentations
Investor News Archive
Major Shareholders & Advisers
Shareholder Information
Corporate Governance
Back
Press Releases
Factsheets
TR-1/Options Press Release Archive
← Back to Media
In the News
Read our CEO Richard Marsden's 2023 Letter
The Need - and Opportunity - to Develop Broad-Spectrum Antivirals by Dr Phillip Monk
ITN Lungs Matter
Synairgen to play key role in respiratory viral infection study
WebMD's John Whyte MD talks to Synairgen CEO Richard Marsden
Synairgen founder Professor Sir Stephen Holgate talks to John Whyte MD of WebMD
Synairgen presents data on antiviral activity of lead asset
Synairgen 'delighted' to get green light for US government-sponsored Phase III trials, starting soon
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
